Skip to main content

Kura Oncology, Inc.

KURA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001422143

In the last 90 days, Kura Oncology, Inc. insiders filed 2 open-market purchases and 8 sales; 221 institutions reported holding it in 13F filings for Q2 2026, worth $953.1M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Kura Oncology, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of KURA: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders148133−15
Shares75.1M75.3M+177.0K (+0.2%)
Value$795.1M$686.9M−$108.2M (−13.6%)

New holders (9)

Institutions that held Kura Oncology, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to KURA in Q3 2023
InstitutionSharesValue% of portfolio
Dark Forest Capital Management LP80,162$731.1K0.06%
Jump Financial, LLC49,614$452.5K0.02%
Balyasny Asset Management LLC46,865$427.4K0.00%
HSBC Holdings PLC33,237$299.8K0.00%
DekaBank Deutsche Girozentrale30,000$262.0K0.00%
Bayesian Capital Management, LP14,026$127.9K0.01%
Axq Capital, LP12,943$118.0K0.04%
Pale Fire Capital SE10,050$91.7K0.01%
Comerica Bank138$1.26K0.00%

Sold out (24)

Institutions that held Kura Oncology, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.